Cited by 1,192Diabetes Treatment and ManagementDiabetes Management and ResearchHeart Failure Treatment and Management

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Open access

Buse, John B., Wexler, Deborah J., Tsapas, Apostolos, Rossing, Peter, Mingrone, Geltrude, Mathieu, Chantal, D’Alessio, David A., Davies, Melanie J.·2020·Diabetes Care

DOI 10.2337/dci19-0066PMC PMC6971782

Open this paper in CoChat — free account Open PDF

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dci19-0066

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citation
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Somemeta-analyses (5,13,14) suggest the presence of heterogeneity in estimates forMACE andCVdeathwithGLP-1 receptor agonists, although this ismostly due to the results of a single trial with lixisenatide.”
Result
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citation
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084

Show all 21 references

Sorted by citations

Items 601–700 of 1,000

Non‐inferiority and clinical superiority of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes
Zaccardi, F., Kloecker, D. E., Khunti, K. K., & Davies, M. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14735 · Cited by 7
Self-citation
Patients’ Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation
Gil, J. E. C., Garnica-Cuéllar, J. C., Terns, P. P., Ferreira‐Hermosillo, A., Canto, J. A. C., Garduño-Pérez, Á. A., Martínez, P. M., Rista, L., Sosa-Caballero, A., Vázquez-Méndez, E., et al. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s355638 · Cited by 7
Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
Du, L., Qin, J., Wang, D., Zhao, Y., Xu, N., Wu, C., & Yuan, J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1028486 · Cited by 7
Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
Nilsson, K., Andersson, E., Persson, S., Karlsdotter, K., Skogsberg, J., Gustavsson, S., JENDLE, J. H., & Carlsson, K. S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14921 · Cited by 7
Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study
Klein, G., Petrone, M., Yang, Y., Hoang, T., Hazlett, S., Hansen, L. B., & Flor, A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01239-1 · Cited by 7
Stroke Prevention
Dopler, B. M. (2023) · Delaware Journal of Public Health · doi:10.32481/djph.2023.08.003 · Cited by 8
Association of fasting blood glucose level with 90-day unfavorable outcome in acute ischemic stroke patients
Xia, Y., Li, L., Li, Y., Hu, M., Zhang, T., Feng, Q., Li, W., Zhu, Y., & Wu, M. (2023) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2023.108049 · Cited by 7
Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus
Mujalli, A., Farrash, W. F., Obaid, A. A., Khan, A. A., Almaimani, R. A., Idris, S., Elzubier, M. E., Khidir, E. B. A., Aslam, A., Minshawi, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417380 · Cited by 7
Insights into the impact of sodium‐glucose cotransporter 2 inhibition on urinary tract malignancy: A two‐sample Mendelian randomization
Han, Z., He, Y., Li, X., Li, S., & Ai, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15490 · Cited by 8
Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial
Kataoka, Y., Kitahara, S., Funabashi, S., Makino, H., Matsubara, M., Matsuo, M., Omura‐Ohata, Y., Koezuka, R., Tochiya, M., Tamanaha, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.03.001 · Cited by 7
Evaluating the Antihyperalgesic Potential of Sildenafil–Metformin Combination and Its Impact on Biochemical Markers in Alloxan-Induced Diabetic Neuropathy in Rats
Pușcașu, C., Zbârcea, C. E., Ungurianu, A., Ștefănescu, E., Chiriță, C., Blebea, N. M., & Negreș, S. (2024) · Pharmaceuticals · doi:10.3390/ph17060783 · Cited by 9
Deciphering the Causal Relationship between Sodium-glucose Cotransporter 2 Inhibition and Cancer Risks: A Comprehensive Mendelian Randomization Study
Zhang, L., Xue, B., Yu, F., Yin, Y., & Jin, S. (2024) · Journal of Cancer · doi:10.7150/jca.96435 · Cited by 7
The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review
Ezhumalai, B., Modi, R., Panchanatham, M., & Kaliyamoorthy, D. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.07.005 · Cited by 10
Real-world evaluation of vascular complications and comorbidities in Portuguese patients with type 2 diabetes: Results from the cMORE study
Alão, S., Silva, T., Leite, A. P., do Rosário, M., Carvalho, C., Coelho, J., Ferreira, H. J., Ferreira, R., Abreu, J., Rosa, M., et al. (2024) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2024.04.011 · Cited by 7
Clinical outcomes in type 2 diabetes patients with chronic heart failure treated with metformin: a meta-analysis
Huang, W., & Zhao, R. (2024) · Endocrine · doi:10.1007/s12020-024-04025-6 · Cited by 8
Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan
Maruyama‐Sakurai, K., Tachimori, H., Saito, E., Kohsaka, S., Segawa, Y., Miyata, H., & Igarashi, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15832 · Cited by 7
Use of sodium‐glucose cotransporter‐2 inhibitors and risk of dementia: A population‐based cohort study
Zhuo, L., Zhang, B., Yin, Y., Sun, Y., Shen, P., Jiang, Z.-Q., Zhan, S., & Zhao, H.-Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16239 · Cited by 7
Therapeutic Potential of Quercetin in Type 2 Diabetes Based on a Network Pharmacology Study
Basaldúa-Maciel, V., Guzmán‐Flores, J. M., Reyes‐Chaparro, A., & Martínez–Esquivias, F. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266361598250212030220 · Cited by 7
Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis
Qiu, M., Liu, S.-Y., Gu, J.-S., Li, K.-K., Li, L.-L., & Ding, L. (2020) · Endocrine · doi:10.1007/s12020-020-02359-5 · Cited by 7
Recomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2
Castillo, G. A., Aroca, G., Buelvas, J., Buitrago, A. F., Carballo-Zárate, V., Cárdenas, J. M., Gómez, E. A., Fériz, K., Lopera, J. M., Enrique Melgarejo, R., et al. (2020) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2020.07.005 · Cited by 7
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
García‐Pérez, L., Boye, K. S., Rosilio, M., Jung, H., Heitmann, E., Norrbacka, K., Federici, M. O., Gentilella, R., Guerci, B., Giorgino, F., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01076-0 · Cited by 7
‘For me, it didn’t seem as drastic a step as being controlled by insulin’: A qualitative investigation of expectations and experiences of non‐insulin injectable therapy among adults with type 2 diabetes
Holmes‐Truscott, E., Schipp, J., Dunning, T. L., Furler, J., Hagger, V. L., Holloway, E. E., Manski-Nankervis, J.-A. E., Shaw, J. E., Skinner, T. C., & Speight, J. (2021) · Diabetic Medicine · doi:10.1111/dme.14681 · Cited by 7
Adipositas und Diabetes
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Selig, L., Blüher, M., & Menzen, M. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1515-8779 · Cited by 7
Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
Hu, S., Wang, S., Qi, C., Gu, S., Shi, C., Mao, L., & Fan, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.831364 · Cited by 7
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Davis, T. M. E., Giczewska, A., Lokhnygina, Y. V., Mentz, R. J., Sattar, N. A., Holman, R. R., & for the EXSCEL Study Group (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01555-z · Cited by 7
GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2030034 · Cited by 7
The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
Viljoen, A., Chubb, B., Malkin, S. J. P., Berry, S., Hunt, B., & Bain, S. C. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01514-1 · Cited by 7
Safety of sodium–glucose c otransporter 2 inhibitors in Asian type 2 diabetes populations
Davidson, J. A., Sukor, N., Hew, F., Mohamed, M., & Hussein, Z. B. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13915 · Cited by 8
Chronic Kidney Disease Stage G4 in a Diabetic Patient Improved by Multi-Disciplinary Treatments Based Upon Literature Search for Therapeutic Evidence
Yanai, H., Yamaguchi, N., & Adachi, H. (2022) · Cardiology Research · doi:10.14740/cr1424 · Cited by 7
Predictors of Follow-Up Appointment No-Shows Before and During COVID Among Adults with Type 2 Diabetes
Sun, C., Perrin, N., Maruthur, N. M., Renda, S., Levin, S., & Han, H.-R. (2022) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2022.0377 · Cited by 7
Skeletal muscle HSF1 prevents insulin resistance by improving glucose utilization
Li, Y., Lin, S., Xu, X., Jin, W., Su, Y., Yuan, F., Zhang, Y., Li, Z., Zhou, Y., Zhu, L., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202201160rr · Cited by 9
Genetic variation of CYP2C9 gene and its correlation with cardiovascular disease risk factors
Rasool, G. S., Al-Awadi, S. J. A., Hussien, A. A., & Al-Attar, M. M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09151-4 · Cited by 7
Prevalence of insulin as a first‐line therapy and associated factors in people with type 2 diabetes in German primary care practices
van den Boom, L., Kaiser, M., & Kostev, K. (2020) · Diabetic Medicine · doi:10.1111/dme.14338 · Cited by 7
Insulin Glargine 300 Units/mL Effectiveness in Patients with T2DM Uncontrolled by Basal Insulin in Real-Life Settings in the Czech Republic
Prázný, M., Flekač, M., Jelínek, P., & Mašková, J. (2020) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2020.103010 · Cited by 7
Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes
Buse, J. B., Holst, I., Knop, F. K., Kvist, K., Thielke, D., & Pratley, R. E. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14381 · Cited by 7
Self-citation
Prevention of Diabetes Macrovascular Complications and Heart Failure
Sattar, N. A. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.004 · Cited by 7
Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
Koufakis, T., Papazafiropoulou, A. K., Makrilakis, K., & Kotsa, K. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07249-0 · Cited by 7
Advances in Diabetes Treatment — Once-Weekly Insulin
Gottlieb, P. A., & Michels, A. W. (2020) · New England Journal of Medicine · doi:10.1056/nejme2031596 · Cited by 7
Flozins — in the light of the latest recommendations
Wróbel, M., Rokicka, D., & Strojek, K. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0098 · Cited by 7
Sulfonylureas and Meglitinides
and, J. T., & Boyle, J. (2022) · doi:10.1002/9781119785033.ch3 · Cited by 7
A drug mix and dose decision algorithm for individualized type 2 diabetes management
Nambiar, M., Bee, Y. M., Chan, Y. E., Mien, I. H., Guretno, F., Carmody, D., Lee, P. C., Chia, S. Y., Salim, N. N. M., & Krishnaswamy, P. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01230-5 · Cited by 8
Comparing the Efficacy of Liraglutide and Semaglutide on Weight Loss: Experience from the Middle East Gulf Region and Literature Review
Nekidy, W. S. E., Hasan, H., Abidi, E., Sayegh, L. A., Dajani, R. Z., El-Kaissi, S., Hegazin, S. B., & Mallat, J. (2025) · Hospital Pharmacy · doi:10.1177/00185787251340645 · Cited by 7
Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease
Yao, Y., Liu, N., Chen, S., Sun, M., & Guo, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03241-8 · Cited by 7
XGBoost based machine learning prediction model for major adverse cardiovascular events after PCI in STEMI patients
Zhang, N., Wang, J., Shen, C., Pei, Y., Li, W., Wang, H., Sun, X., Qi, Y.-F., Wang, Y., Liu, Y., et al. (2026) · Scientific Reports · doi:10.1038/s41598-025-34441-1 · Cited by 6
The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study
Kvist, A. V., Andersen, S. S., Vestergaard, P., & Viggers, R. (2026) · Osteoporosis International · doi:10.1007/s00198-026-07950-6 · Cited by 6
Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study
Inagaki, N., Nishimoto, T., Nishiya, Y., & Nitta, D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2107200 · Cited by 6
Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
Gu, S., Hu, X., Zhen, X., Shi, L., Shao, H., Sun, X., Gu, Y., Huang, M., & Dong, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185435 · Cited by 6
Older Adults with Type 2 Diabetes Treated with Metformin: AME-MET Study - A Multicentric Real-world Study in Italy
Castellano, E., Borretta, G., Attanasio, R., Boriano, A., Agrimi, D., Argese, N., Crescenti, C., Disoteo, O., Fusco, A., Gabellieri, E., et al. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666221115091621 · Cited by 6
Substituent effects of sulfonamide derivatives of metformin that can dually improve cellular glucose utilization and anti-coagulation
Zajda, A., Sikora, J., Hynninen, M., Tampio, J., Huttunen, K. M., & Markowicz-Piasecka, M. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110381 · Cited by 7
Finerenone and other future therapeutic options for Alport syndrome
Pearce, H., & Mabillard, H. R. (2023) · Journal of Rare Diseases · doi:10.1007/s44162-023-00022-x · Cited by 7
Proarrhythmic Lipid Inflammatory Mediators: Mechanisms in Obesity Arrhythmias
Taqanaki, P. B., Aromolaran, K. A., & Aromolaran, A. S. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70012 · Cited by 6
Modification of the of the cardiometabolic profile using combined therapy of the angiotensin receptor-neprilysin inhibitor and empagliflozin in comorbid patients with Chronic Heart Failure and type 2 Diabetes Mellitus
Васильевна, Ц. О., Васильевна, В. В., & VIu, M. (2020) · Kardiologiia · doi:10.18087/cardio.2020.5.n840 · Cited by 6
Metaanálisis para evaluar el riesgo de infecciones respiratorias y síndrome de distrés respiratorio del adulto con los agonistas del receptor del péptido similar al glucagón tipo 1 en los ensayos de seguridad cardiovascular: consecuencias útiles para la pandemia de COVID-19
Patoulias, D., Boulmpou, A., Imprialos, K. P., Stavropoulos, K., Papadopoulos, C. E., & Doumas, M. N. (2021) · Revista Clínica Española · doi:10.1016/j.rce.2021.04.001 · Cited by 6
Evolving Concepts of Type 2 Diabetes Management
Abushamat, L. A., & Reusch, J. E. B. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.003 · Cited by 6
Glucose-lowering therapy in patients undergoing percutaneous coronary intervention
Johansson, I., Dicembrini, I., Mannucci, E., & Cosentino, F. (2021) · EuroIntervention · doi:10.4244/eij-d-20-01250 · Cited by 6
Are Differences in Inflammatory Markers between Patients with and without Hypertension-Mediated Organ Damage Influenced by Circadian Blood Pressure Abnormalities?
Vázquez-Agra, N., Marques-Afonso, A.-T., Cruces‐Sande, A., Novo‐Veleiro, I., Lopez-Paz, J.-E., Pose‐Reino, A., & Ameijeiras, Á. H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051252 · Cited by 7
Real‐world outcomes of addition of insulin glargine 300 U/ mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study
Bailey, T. S., Gill, J., Merwyn Jones, S., Shenoy, L., Nicholls, C. J., & Westerbacka, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14739 · Cited by 6
Adipositas – eine behandlungsbedürftige chronische Erkrankung
Meyhöfer, S., Lautenbach, A., & Serfling, G. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1657-2047 · Cited by 6
Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data
Kuß, O., Akbulut, C., Schlesinger, S., Georgiev, A., Kelm, M., Roden, M., & Wolff, G. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01917-9 · Cited by 6
Effect of Pre-Meal Metformin With or Without an Acute Exercise Bout on Postprandial Lipemic and Glycemic Responses in Metabolic Syndrome Patients: A Randomized, Open Label, Crossover Study
Methnani, J., Hajbelgacem, M., Ach, T., Chaieb, F., Sellami, S., Bouslama, A., Zaouali, M., Omezzine, A., & Bouhlel, E. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231156318 · Cited by 7
Results of semaglutide in patients older than 70 years, a real-world study of efficacy and safety
de Lucas, M. D. G., Perez-Belmonte, L. M., Avilés, B., Jiménez-Millán, A., Rivas‐Ruiz, F., & Miramontes‐González, J. P. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.03985-4 · Cited by 6
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
Gracen, L., Muthukumara, W., Aikebuse, M., Russell, A. W., O’Beirne, J. P., Irvine, K. M., Williams, S., Puri, G., Valery, P. C., Hayward, K. L., et al. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101142 · Cited by 6
The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Hollander, P. A., Krause-Steinrauf, H. J., Butera, N. M., Kazemi, E. J., Ahmann, A., Fattaleh, B. N., Johnson, M. L., Killean, T., Lagari, V. S., Larkin, M., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0516 · Cited by 6
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study
de Lucas, M. D. G., Caballero, I., Fernández‐García, J. C., Domínguez-Rodríguez, M., Moreno-Moreno, P., Jiménez-Millán, A., Botana-López, M. A., Avilés, B., Merino-Torres, J. F., Soto, A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240279 · Cited by 8
Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial
Gilbert, M. P., Skelly, J. M., Hernandez, A. F., Green, J. B., Krychtiuk, K. A., Granger, C. B., Leiter, L. A., McMurray, J. J. V., Prato, S. D., & Pratley, R. E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15479 · Cited by 6
Development and validation of a nomogram superior to CHADS2 and CHA2DS2-VASc models for predicting left atrial appendage dense spontaneous echo contrast/left atrial appendage thrombus
Sun, S., Ma, C., Li, Y., Lin, J., & Qian, X. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-288 · Cited by 6
Sodium–glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care
Verma, S., Klug, E., Mareev, V. Y., Kobalava, Z. D., Connelly, K. A., Arıcı, M., Berwanger, O. B., Santoso, A., Mehta, R., Meglis, G., et al. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000774 · Cited by 6
Obesity and Diabetes
Aberle, J., Lautenbach, A., Meyhöfer, S., Schmid, S. M., Selig, L., & Blüher, M. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1284-6050 · Cited by 7
Healthcare resource utilization after initiation of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors or other glucose‐lowering drugs in Japanese patients with type 2 diabetes
Kohsaka, S., Takeda, M., Kidani, Y., & Yajima, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14289 · Cited by 6
Glucagon-like peptide-1 Receptor Agonists and the Cardiorenal Axis in Type 2 Diabetes: A Focus On Dulaglutide
MacIsaac, R. J. (2021) · Future Cardiology · doi:10.2217/fca-2020-0210 · Cited by 6
Sodium-glucose cotransporter 2 inhibitors: a practical guide for the Dutch cardiologist based on real-world experience
Zwart, K., Velthuis, S., Polyukhovych, Y. V., Mosterd, A., Smidt, L. C. A., Serné, E. H., van Raalte, D. H., Elders, P. J. M., Handoko, M. L., & Oldenburg-Ligtenberg, P. C. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01580-9 · Cited by 6
Management of Hyperglycemia in Hospitalized, Non–Critically Ill Adults
Chang, L. L., Umpierrez, G. E., & Inzucchi, S. E. (2022) · New England Journal of Medicine · doi:10.1056/nejmclde2204691 · Cited by 6
A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China
Jiang, Y., Liu, R., Xuan, J., Lin, S., Zheng, Q., & Pang, J. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01255-w · Cited by 6
Diabetic Kidney Disease
Nicholas, S. B., & Tuttle, K. R. (2020) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2020.19.2.5 · Cited by 6
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Kataria, A., & Argyropoulos, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_25 · Cited by 6
Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review
Birker, S., Meier, J. J., & Nauck, M. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-25296-x · Cited by 6
Bitter Phytochemicals Acutely Lower Blood Glucose Levels by Inhibition of Glucose Absorption in the Gut
Jackson, K. M. P., Mhawish, R., & Komarnytsky, S. (2024) · Endocrines · doi:10.3390/endocrines5030022 · Cited by 5
Comparing the Efficacy and Long-Term Outcomes of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Metformin, and Insulin in the Management of Type 2 Diabetes Mellitus
Khan, F., Hussain, T., Chaudhry, T. Z., Payal, F., Shehryar, A., Rehman, A., Ramadhan, A., Hayat, M. T., Dabas, M. M., & Khan, M. (2024) · Cureus · doi:10.7759/cureus.74400 · Cited by 7
Impact of SGLT2 Inhibitor Therapy on Patients Undergoing Cardiac Surgery
Taghiyev, Z. T., Beier, L.-M., Leweling, C., Gunkel, S., Sadowski, K. M., Aßmus, B., & Böning, A. (2025) · The Thoracic and Cardiovascular Surgeon · doi:10.1055/a-2616-4962 · Cited by 6
Dietary interventions and glycaemic control in type 2 diabetes: A systematic review and meta-analysis
Marume, A., Chidoko, E., & Chirenda, J. (2025) · Journal of Public Health in Africa · doi:10.4102/jphia.v16i1.1325 · Cited by 12
The Impact of Different Antidiabetic Drugs on Fracture Risk in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials With a Focus on SGLT2 Inhibitors
Admani, B., Raza, F. Z., Siddiqui, F., Ashraf, M. T., Khan, M. K., Habib, I., Usman, A., Mansoor, B. M., Nadeem, Z., Ghaffer, R. J., et al. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100115 · Cited by 5
Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis
Wang, Y., Wu, H., Yang, J., Ma, J., Li, H., He, X., Xiao, Y., & Pan, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1486655 · Cited by 7
SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Ahmed, A. A. O., Ahmed, O., Ahmed, R. A. O., Ahmed, R. A. O., Mohammed, M. A. E. A., Ahmed, Y., Abbas, M., Ibrahim, M. A. A., Abakar, M. E. M., Dahab, K. E. M., et al. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05455-4 · Cited by 5
Global trends and focuses of GLP-1RA in renal disease: a bibliometric analysis and visualization from 2005 to 2022
Meng, Y., Wang, Y., Fu, W., Zhang, M., Huang, J., Wu, H., & Sun, L. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02575-6 · Cited by 6
Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial
Xu, M., Sun, K., Xu, W., Wang, C., Yan, D., Li, S., Cong, L., Pi, Y., Song, W., Sun, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03089-x · Cited by 6
The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial—Study Design and Protocol
Novodvorský, P., Thieme, L., Laňková, I., Mráz, M., Taybani, Z. J., Bótyik, B., Stella, P., Vytasil, M., Lauand, F., Bonnemaire, M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01582-x · Cited by 5
Hypoglycemic drugs, circulating inflammatory proteins, and gallbladder diseases: A mediation mendelian randomization study
Wang, Z.-Q., Zhang, J., Tang, X., & Zhou, J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111882 · Cited by 5
Differences between Type 2 Diabetes Mellitus and Obesity Management: Medical, Social, and Public Health Perspectives
Lim, S. K., Nam, G. E., & Sharma, A. M. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0278 · Cited by 5
In Vivo Antidiabetic and Antilipidemic Effect of Thiazolidine-2,4-Dione Linked Heterocyclic Scaffolds in Obesity-Induced Zebrafish Model
Galal‐Khallaf, A., Mousa, D., Atyah, A., El-Bahnsawye, M., Hussein, M. K. A., Sayed, I. E. T. E., Elmongy, E. I., Binsuwaidan, R., El‐Torgoman, A. M., Abdel‐Bary, H. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18071023 · Cited by 5
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Yoo, S. J., Chang, S., Sohn, T. S., Kwon, H., Lee, J. M., Moon, S., Proot, P., Paldánius, P. M., & Yoon, K. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0173 · Cited by 6
SGLT2-Inhibitoren: Was gibt es Neues?
Dumann, E., & Menne, J. (2021) · Der Nephrologe · doi:10.1007/s11560-021-00511-4 · Cited by 6
GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs
McGuire, D. K., & Pagidipati, N. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00212-6 · Cited by 5
Manejo de perfiles de pacientes con diabetes mellitus tipo 2 en la práctica clínica de la atención primaria en España: Programa CONTROVERTI2
Obaya, J. C., Jiménez, S., Osoro, I. A., Barrera, F., Soidán, F. J. G., & Cuenca, A. M. C. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.07.009 · Cited by 5
Intersection Between Diabetes and Heart Failure: Is SGLT2i the “One Stone for Two Birds” Approach?
Zhang, Q., Kang, Y., Tang, S., & Yu, C. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01591-3 · Cited by 5
Are There Different Viewpoints About the Management of Type 2 Diabetes Mellitus and Comorbidities? A Multidisciplinary Spanish Qualitative Research
Cos, X., Gómez‐Huelgas, R., & Peralta, F. G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01188-7 · Cited by 5
Role of epicardial fat thickness for prediction of proliferative diabetic retinopathy
Abide, S., Tuba, K., Alkan, Y., Coşgun, M., Umit, D., Ulaş, F., Güneş, Y., & Sıncer, İ. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-01040-5 · Cited by 5
Multimodal Treatment Approaches to Chronic Diseases
Maraş, G., & Sürme, Y. (2022) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2021.00079 · Cited by 5
Effect of Resveratrol in Melinjo Seed (Gnetum gnemon L.) Extract on Type 2 Diabetes Mellitus Patients and its Possible Mechanism: A Review
Ariyanto, E. F., Danil, A. S., Rohmawaty, E., Sujatmiko, B., & Berbudi, A. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220228160908 · Cited by 5
Decision-making on listing new medicines for public funding in New Zealand: the case of ‘new’ type 2 diabetes medications
Sarkisova, F., Lessing, C., & Stretton, C. (2022) · Journal of Primary Health Care · doi:10.1071/hc21122 · Cited by 5
Efficacy and safety outcomes of dulaglutide by baseline HbA1c : A post hoc analysis of the REWIND trial
Franek, E., Gerstein, H. C., Riddle, M. C., Nicolay, C., Hickey, A., Botros, F. T., & Loo, L. S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14760 · Cited by 7

Authors: Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J.
Affiliations: University of North Carolina at Chapel Hill (US)
Harvard University (US)
Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
University of Copenhagen (DK)
Università Cattolica del Sacro Cuore (IT)
Universitair Ziekenhuis Leuven (BE)
Duke University (US)
University of Leicester (GB)
Corresponding author: Davies, Melanie J.
ORCID: Buse, John B.
Wexler, Deborah J.
Tsapas, Apostolos
Rossing, Peter
Mingrone, Geltrude
Mathieu, Chantal
D’Alessio, David A.
Davies, Melanie J.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2019-12-19
Volume: 43
Issue: 2
Pages: 487-493
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dci19-0066
PMC: PMC6971782
OpenAlex: W4253996779
Cited by: 1,192
References: 21
Citations by year: 2026: 54 · 2025: 79 · 2024: 128 · 2023: 162 · 2022: 277 · 2021: 279 · 2020: 212
FWCI: 155.76
Type: journal article
Language: en
Update notices: correction (2020-07-01)
Open access: bronze
doi.org
Licence: www.diabetesjournals.org/content/license (vor, 32 d)
Locations: Diabetes Care (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
Lirias (submittedVersion)
PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
Funders: American Diabetes Association
European Association for the Study of Diabetes
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: hyperglycemia management, type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, heart failure hospitalization, heart failure with reduced ejection fraction, chronic kidney disease progression, HbA1c targets, cardiovascular risk stratification

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks